Your session is about to expire
← Back to Search
Device
Braive™ GMS for Scoliosis (BRAIVE IDE Trial)
N/A
Waitlist Available
Research Sponsored by Medtronic Spinal and Biologics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Has kyphosis ≤ 40 degrees with a sagittal thoracic modifier N or negative
Has a diagnosis of juvenile or adolescent idiopathic scoliosis
Must not have
Has undergone previous spinal fusion procedure(s) at the affected levels
Is unwilling or unable to return for follow-up visits and/or follow intra-operative and/or postoperative instructions
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 3, 6, 12, 18, 24 months, and annually until skeletal maturity is reached.
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to test the benefits and safety of the Braive™ GMS device in children with worsening scoliosis. The device helps straighten their spine and prevent further curvature.
Who is the study for?
This trial is for children and adolescents with juvenile or adolescent idiopathic scoliosis. They should have a main thoracic Cobb angle of 30-60 degrees, be skeletally immature (Sanders Score of 2-5), and not responded to conservative treatments. Participants must not have had prior chest surgery, spinal abnormalities, severe lung disease, or any condition that could interfere with the study.
What is being tested?
The Braive™ Growth Modulation System (Braive™ GMS) is being tested for its safety and potential benefits in treating progressive pediatric scoliosis. The study will assess how well this system can manage the curvature of the spine in young patients.
What are the potential side effects?
While specific side effects are not listed here, potential risks may include reactions to implant materials such as inflammation or infection at the site of surgery, discomfort from the device itself, and general surgical risks like bleeding.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My spine curvature is less than or equal to 40 degrees.
Select...
I have been diagnosed with scoliosis since I was a child or teenager.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had spinal fusion surgery at the affected levels.
Select...
I cannot or will not follow up or follow instructions after surgery.
Select...
I am at high risk for infections or have a weak immune system.
Select...
I have had surgery on the same or opposite side of my chest before.
Select...
I have a severe long-term lung condition.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to 3, 6, 12, 18, 24 months, and annually until skeletal maturity is reached.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 3, 6, 12, 18, 24 months, and annually until skeletal maturity is reached.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Summary of device-related adverse events up to 24 months
Secondary study objectives
Assessment of device deficiency up to 24 months
Assessment of procedure-related adverse events up to 24 months
Assessment of secondary Spinal surgeries related to the original study device up to 24 months.
+12 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Braive™ Growth Modulation System (Braive™ GMS)Experimental Treatment1 Intervention
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Adolescent Idiopathic Scoliosis (AIS) include bracing and surgical interventions. Bracing works by applying external pressure to the spine to halt the progression of curvature, which is crucial for patients who are still growing to prevent severe deformities.
Surgical options, such as spinal fusion or growth modulation systems like the Braive™ GMS, physically correct the spinal curvature and guide spinal growth over time. These treatments are essential for managing AIS as they help maintain spinal function and improve quality of life by addressing the structural issues of the spine.
Find a Location
Who is running the clinical trial?
Medtronic Spinal and BiologicsLead Sponsor
55 Previous Clinical Trials
10,578 Total Patients Enrolled
Exponent, Inc.UNKNOWN
1 Previous Clinical Trials
200 Total Patients Enrolled
Medical College of WisconsinOTHER
633 Previous Clinical Trials
1,181,685 Total Patients Enrolled
Medical Metrics Diagnostics, IncIndustry Sponsor
13 Previous Clinical Trials
1,754 Total Patients Enrolled
SyntactxNETWORK
22 Previous Clinical Trials
1,147,429 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had spinal fusion surgery at the affected levels.My spine curvature is less than or equal to 40 degrees.I cannot or will not follow up or follow instructions after surgery.I have been diagnosed with scoliosis since I was a child or teenager.I am at high risk for infections or have a weak immune system.I have had surgery on the same or opposite side of my chest before.I have a severe long-term lung condition.My doctor says I have weak bones that could affect surgery.
Research Study Groups:
This trial has the following groups:- Group 1: Braive™ Growth Modulation System (Braive™ GMS)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.